The purpose of this Notice is to encourage currently funded NCI extramural investigators to apply for administrative supplements to conduct systematic evidence reviews assessing the state of the science on the clinical utility (CU) of cancer-site specific polygenic risk scores (PRS) for cancer risk assessment and inform future trials and research directions for clinical translation and implementation. The goals of this supplement opportunity are to 1) identify the potential for CU of cancer-site specific PRS for cancer risk assessment; 2) describe the state of the science in terms of cancer-site specific PRS development and evaluation; 3) assess the current evidence for efficacy and/or effectiveness of PRS CU and potential benefits and harms of their clinical use (including consideration of available screening and prevention interventions based on risk); and 4) propose criteria and optimal study designs and methods for which PRS are candidates for evaluation of CU through clinical trials.
Brief Description